MENLO PARK, Calif.–(BUSINESS WIRE)–#PrecisionOncology–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with Personalis’ leading ImmunoID NeXT™ tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that can now be monitored over time from blood samples. NeXT Liquid Biopsy monitors over twenty times more genes than the majority of liquid biopsy cancer panels on the market today. These capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies.
Personalis CEO, John West, said, “Solid tumor biopsies and liquid biopsies complement each other, and it is important to utilize both in cancer research. Solid tumor biopsies can yield information about mutations, gene expression, the tumor microenvironment, and immune cells that have infiltrated the tumor, while liquid biopsies can track mutations and detect new mutations over time in response to treatment. By combining NeXT Liquid Biopsy with ImmunoID NeXT, researchers now have a powerful tool to address tumor heterogeneity, longitudinally monitor clonal and subclonal dynamics, identify acquired resistance mechanisms, and access key areas of tumor biology not typically included in targeted liquid biopsy panels. We strongly believe this will provide a powerful framework for translational research, and the development of next-generation cancer therapeutics to overcome therapy resistance and cancer progression.”
Mr. West added, “Through our collaborations program, we are encouraged by our partners’ response to NeXT Liquid Biopsy. NeXT Liquid Biopsy represents a new capability in the market and we look forward to working closely with our first customers. This is just the first step in Personalis’ liquid biopsy product portfolio and we are excited for further developments in this area.”
NeXT Liquid Biopsy is immediately available for order.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements relating to the capabilities, availability or benefits of NeXT Liquid Biopsy, potential advancement of or growth opportunities for Personalis’ business, expansion of Personalis’ market presence in immuno-oncology, the company’s services for the VA Million Veterans Program, and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
Contacts for Personalis, Inc.
Investor Relations Contact for Personalis: